The week of June 24 in review, featuring clinical articles and physician interviews on an FDA approval, crizotinib in NSCLC, sorafenib in DTC, and more.
TweetThe FDA approved an update to the product labeling for dasatinib (Sprycel), Bristol-Myers Squibb Company and Otsuka America Pharmaceutical announced on June 20.
Mark R. Gilbert, MD, a professor of neuro-oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, reviews the trial design and findings from the RTOG 0825 phase III study that evaluated bevacizumab in patients with newly diagnosed glioblastoma.
Interim findings from a randomized, global, phase III study presented at ASCO 2013 indicate that sorafenib (Nexavar) nearly doubled progression-free survival (PFS) for patients with differentiated thyroid cancer (DTC) resistant to standard radioactive iodine therapy (RAI).
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.
The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type. Not only does carfilzomib demonstrate activity in a relapsed and refractory setting, it has a superior toxicity profile as well.
A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, Sartor says, there was not much clinical progress in prostate cancer presented, as there was no new positive phase III data.
Head and neck squamous cell carcinomas (HNSCCs) have different patterns of genetic alterations, some of which may be actionable or druggable, according to a study by The Cancer Genome Atlas (TCGA) that was presented at the AACR 2013 annual meeting.
Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses the background, rationale, and results for the exploration of maintenance pazopanib as a treatment for patients with advanced ovarian cancer.
Patients with chronic lymphocytic leukemia (CLL) and patients with mantle cell lymphoma (MCL) showed high response rates to therapy with ibrutinib.
Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.
The second-generation tyrosine kinase inhibitor (TKI) dacomitinib, designed to treat non-small-cell lung cancer (NSCLC), is being evaluated in an international phase III clinical trial that will measure the drug’s effectiveness as a first-line treatment in a genetic subset of patients with locally advanced or metastatic disease.
Mario Sznol, MD, a professor of medical oncology at the Yale Cancer Center in New Haven, Connecticut, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.